|
|
Other links at Articles > Hematology-Oncology |
| 2. |
Bevacizumab SAiLs On in Phase 4 NSCLC Safety Study
|
|
|
Toxicities associated with bevacizumab are manageable when the drug is delivered as first-line therapy with chemotherapy combinations to patients with nonsquamous nonsmall-cell lung cancer (NSCLC). Medscape Medical News
|
|
|